RxSight Q2 revenue $20.8M (+83% YoY); raises FY2023 guidance; pays off $40M debt

RxSight, Inc.

2023-Q2 EPS reported -$0.82 revenue$38,299,000

Q2 revenue $20.8M (+83% YoY); net loss $(13.8)M vs $(16.7)M last year.
Raised FY2023 revenue guidance to $81-86M (prior $79-84M); gross margin 58-60%.
LAL procedure volumes 12,622 (+134% YoY); LDD installed base 523 (+78% YoY).
Paid off $40M debt in Q2 and early Q3, eliminating ~$5.6M annual interest expense.
Raised ~$31.3M net from ATM in Q2 and early Q3 to fund debt repayment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RxSight, Inc. reported three and six months ended June 30, 2023 results: revenue $20.8 million, net income $(13.8) million, EPS $(0.40) per basic and diluted share. Guidance raised.

Period: three and six months ended June 30, 2023
Revenue: $20.8 million
Net income: $(13.8) million
EPS: $(0.40) per basic and diluted share
Guidance: raised
Result: reported results

Exact text from the filing

following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights • Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting: • The sale of 67 Light Delivery Devices (LDDTMs), representing a 37% increase in unit sales compared to

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.